Rates of Emergence of HIV Drug Resistance in Resource-Limited Settings: A Systematic Review

Abstract

Background

The increasing availability of antiretroviral therapy (ART) has improved survival and quality of life for many infected with HIV, but can also engender drug resistance. This review summarizes the available information on drug resistance in adults in resource-limited settings.

Methods

The online databases PubMed and Google Scholar, pertinent conference abstracts and references from relevant articles were searched for publications available before November 2011. Data collected after ART rollout were reviewed.

Results

A total of 7 studies fulfilled the criteria for the analysis of acquired drug resistance and 22 fulfilled the criteria for the analysis of transmitted drug resistance (TDR). Acquired resistance was detected in 7.2% of patients on ART for 6–11 months, 11.1% at 12–23 months, 15.0% at 24-35 months, and 20.7% at ≥36 months. Multi-class drug resistance increased steadily with time on ART. The overall rate of TDR in all resource-limited countries studied was 6.6% (469/7,063). Patients in countries in which ART had been available for ≥5 years were 1.7x more likely to have TDR than those living in a country where ART had been available for <5 years (P<0.001). The reported prevalence of TDR was 5.7% (233/4,069) in Africa, 7.6% (160/2,094) in Asia and 8.4% (76/900) in Brazil.

Conclusions

The emergence of drug resistance following access to ART in resource-limited settings resembles what was seen in resource-rich countries and highlights the need for virological monitoring for drug failure, drug resistance testing and alternative drug regimens that have proven beneficial in these resource-rich settings.

References

Joint United Nations Programme on HIV/AIDS. UNAIDS World AIDS Day Report 2011. (Accessed 7 December 2012.) Available from http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdf.

Bendavid

, Bhattacharya

The president's emergency plan for AIDS relief in Africa: an evaluation of outcomes. Ann Intern Med 2009; 150: 688–695.

Mtambo

, Chan

, Shen

Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings. HIV Med 2012; 13: 141–147.

Gupta

, Hill

, Sawyer

A.W.

, Pillay

Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47: 712–722.

Cozzi-Lepri

, Paredes

, Phillips

The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI. HIV Med 2012; 13: 62–72.

Bannister

W.P.

, Cozzi-Lepri

, Kjaer

Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J Antimicrob Chemother 2011; 66: 901–911.

von Wyl

, Yerly

, Burgisser

Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis 2009; 48: 979–987.

Truong

H.H.M.

, Kellogg

T.A.

, McFarland

Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. PLoS ONE 2011; 6: e25281.

Taniguchi

, Nurutdinova

, Grubb

J.R.

Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy. AIDS Res Hum Retroviruses 2012; 28: 259–264.

10.

Buckton

A.J.

, Prabhu

, Motamed

Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance. HIV Med 2011; 12: 250–254.

11.

Walensky

R.P.

, Ciaranello

A.L.

, Park

J.E.

, Freedberg

K.A.

Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis 2010; 51: 85–92.

12.

D'Aquila

R.T.

, Johnson

V.A.

, Welles

S.L.

Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401–408.

13.

Havlir

D.V.

, Marschner

I.C.

, Hirsch

M.S.

Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998; 339: 1261–1268.

14.

Miller

, Phillips

, Rottmann

Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 1998; 177: 1521–1532.

15.

Rey

, Hughes

, Pi

J.T.

, Winters

, Merigan

T.C.

, Katzenstein

D.A.

HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 203–208.

16.

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264–269.

17.

Bennett

D.E.

, Camacho

R.J.

, Otelea

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4: e4724.

18.

Johnson

V.A.

, Brun-Vezinet

, Clotet

Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18: 156–163.

19.

Stanford University HIV Drug Resistance Database. (Accessed 12 April 2011.) Available from http://hivdb.stanford.edu/index.html.

20.

Agence Nationale de Recherche sur le SIDA. ANRS HIV-1 genotypic drug resistance interpretation's algorithims. (Updated July 2009. Accessed 12 April 2011.) Available from http://www.hivfrenchresistance.org/archives.html.

21.

Shafer

R.W.

, Rhee

S.Y.

, Pillay

HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21: 215–223.

22.

International Treatment Preparedness Coalition. Missing the target #5: improving AIDS drug access and advancing health care for all. (Updated December 2007. Accessed 12 August 2011.) Available from http://aidsdatahub.org/dmdocuments/2007_Improving_AIDS_Drug_Access_and_Advancing_Health_Care_for_All.pdf.pdf.

23.

United Nations. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. (Updated 2011. Accessed 10 April 2011.) Available from http://millenniumindicators.un.org/unsd/methods/m49/m49regin.htm#africa.

24.

Aghokeng

A.F.

, Kouanfack

, Laurent

Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS 2011; 25: 2183–2188.

25.

Price

M.A.

, Wallis

C.L.

, Lakhi

Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses 2011; 27: 5–12.

26.

Monleau

, Faihun

, Affolabi

Antiretroviral drug resistance in HIV-1 infected patients receiving antiretroviral treatment in routine clinics in Cotonou, Benin. Journal of AIDS and HIV Research Vol 2011; 3: 114–120.

27.

Messou

, Chaix

M.L.

, Gabillard

Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J Acquir Immune Defic Syndr 2011; 56: 356–364.

28.

Burda

S.T.

, Viswanath

, Zhao

HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. J Med Virol 2010; 82: 187–196.

29.

Kouanfack

, Montavon

, Laurent

Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis 2009; 48: 1318–1322.

30.

Muwonga

, Edidi

, Butel

Resistance to antiretroviral drugs in treated and drug-naive patients in the Democratic Republic of Congo. J Acquir Immune Defic Syndr 2011; 57 Suppl 1: S27–S33.

31.

Wang

, Yang

, Li

Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China. Curr HIV Res 2011; 9: 103–111.

32.

Dagnra

A.Y.

, Vidal

, Mensah

High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. J Int AIDS Soc 2011; 14: 30.

33.

Soria

, Porten

, Fampou-Toundji

J.C.

Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Antivir Ther 2009; 14: 339–347.

34.

Hamers

R.L.

, Wallis

C.L.

, Kityo

HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11: 750–759.

35.

Sungkanuparph

, Oyomopito

, Sirivichayakul

HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clin Infect Dis 2011; 52: 1053–1057.

36.

Dean

, Ta Thi

T.H.

, Dunford

Prevalence of HIV type 1 antiretroviral drug resistance mutations in Vietnam: a multicenter study. AIDS Res Hum Retroviruses 2011; 27: 797–801.

37.

Liao

, Xing

, Shang

The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr 2010; 53 Suppl 1: S10–S14.

38.

Yang

, Nguyen

B.D.

, Bile

, Marum

, Wagar

, Nkengasong

Global surveillance of transmitted hiv-1 drug resistance in PEPFAR-supported countries using a broadly sensitive genotyping assay. 18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 619.

39.

Ndembi

, Hamers

, Sigaloff

Increasing primary HIV-1 drug resistance among recently infected persons in Uganda, East Africa. 18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 621.

40.

Soares

, Vergara

, Sucupira

M.C.

Prevalence of transmitted HIV-1 antiretroviral resistance among patients initiating ART in Brazil: a surveillance using dried blood spots. 18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 624.

41.

, Le

, Torok

HIV-1 drug resistance in antiretroviral-naïve patients with HIV-associated tuberculous meningitis in Ho Chi Minh City, Vietnam. 18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 625.

42.

Apisarnthanarak

, Jirayasethpong

, Sa-nguansilp

Antiretroviral drug resistance among antiretroviral-naive persons with recent HIV infection in Thailand. HIV Med 2008; 9: 322–325.

43.

Bussmann

, de la Hoz Gomez

, Roels

T.H.

Prevalence of transmitted HIV drug resistance in Botswana: lessons learned from the HIVDR-Threshold Survey conducted among women presenting for routine antenatal care as part of the 2007 national sentinel survey. AIDS Res Hum Retroviruses 2011; 27: 365–372.

44.

Bansode

, Drebert

Z.J.

, Travers

S.A.

Drug resistance mutations in drug-naive HIV type 1 subtype C-infected individuals from rural Malawi. AIDS Res Hum Retroviruses 2011; 27: 439–444.

45.

Mosha

, Urassa

, Aboud

Prevalence of genotypic resistance to antiretroviral drugs in treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant forms in Dar es Salaam, Tanzania. AIDS Res Hum Retroviruses 2011; 27: 377–382.

46.

Derache

, Maiga

A.I.

, Traore

Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother 2008; 62: 456–463.

47.

Djoko

C.F.

, Rimoin

A.W.

, Vidal

High HIV type 1 group M pol diversity and low rate of antiretroviral resistance mutations among the uniformed services in Kinshasa, Democratic Republic of the Congo. AIDS Res Hum Retroviruses 2011; 27: 323–329.

48.

Carvalho

B.C.

, Cardoso

L.P.

, Damasceno

, Stefani

M.M.

Moderate prevalence of transmitted drug resistance and interiorization of HIV type 1 subtype C in the inland North State of Tocantins, Brazil. AIDS Res Hum Retroviruses 2011; 27: 1081–1087.

49.

Inocencio

L.A.

, Pereira

A.A.

, Sucupira

M.C.

Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV. J Int AIDS Soc 2009; 12: 20.

50.

Sprinz

, Netto

E.M.

, Patelli

Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil. AIDS Res Hum Retroviruses 2009; 25: 861–867.

51.

Yaotsè

D.A.

, Nicole

, Roch

N.F.

, Mireille

P.D.

, Eric

, Martine

Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients. Infect Genet Evol 2009; 9: 646–652.

52.

El-Khatib

, Katzenstein

, Marrone

Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS ONE 2011; 6: e17518.

53.

Fox

M.P.

, Sanne

I.M.

, Conradie

Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/ microl is associated with improved treatment outcomes in South Africa. AIDS 2010; 24: 2041–2050.

54.

Severe

, Juste

M.A.

, Ambroise

Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363: 257–265.

55.

Walensky

R.P.

, Wolf

L.L.

, Wood

When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009; 151: 157–166.

56.

Obiako

O.R.

, Murktar

H.M.

, Ogoina

Antiretroviral drug resistance–implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries. Niger J Med 2010; 19: 352–360.

57.

Little

S.J.

, Frost

S.D.

, Wong

J.K.

Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82: 5510–5518.

58.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 27 March 2012. Accessed 12 September 2012.) Available from http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

59.

Thompson

M.A.

, Aberg

J.A.

, Hoy

J.F.

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308: 387–402.

60.

Gill

V.S.

, Lima

V.D.

, Zhang

Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50: 98–105.

61.

Murphy

R.A.

, Sunpath

, Lu

Outcomes after virologic failure of first-line ART in South Africa. AIDS 2010; 24: 1007–1012.

62.

Tuboi

S.H.

, Pacheco

A.G.

, Harrison

L.H.

Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings. J Acquir Immune Defic Syndr 2010; 53: 70–77.

63.

Kimmel

A.D.

, Weinstein

M.C.

, Anglaret

Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010; 54: 258–268.

64.

World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. (Updated 2010. Accessed 2 August 2011.) Available from http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.

65.

Hong

S.Y.

, Jonas

, Dumeni

Population-based monitoring of HIV drug resistance in Namibia with early warning indicators. J Acquir Immune Defic Syndr 2010; 55: 27–31.

66.

Hirsch

M.S.

, Gunthard

H.F.

, Schapiro

J.M.

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47: 266–285.